{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:31:53Z","timestamp":1793413913838,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s43441-026-01026-7","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T13:39:51Z","timestamp":1785332391000},"page":"1612-1618","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Regulatory Alignment on Surrogate Endpoints for Slowly Progressive Ultra-Rare Neurological Diseases: Bridging the Gap Between Biomarker Science and Global Regulatory Acceptance"],"prefix":"10.1007","volume":"60","author":[{"given":"Shihshuan","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenghan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"issue":"1","key":"1026_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ymgme.2008.10.003","volume":"96","author":"RC Griggs","year":"2009","unstructured":"Griggs RC, Batshaw M, Dunkle M, et al. Clinical research for rare disease: opportunities, challenges, and solutions. Mol Genet Metab. 2009;96(1):20\u20136.","journal-title":"Mol Genet Metab"},{"issue":"6","key":"1026_CR2","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1007\/s43441-025-00853-4","volume":"59","author":"C Wang","year":"2025","unstructured":"Wang C, Di J, Ghadessi M, et al. Insights on clinical development of cell and gene therapy for rare diseases. Ther Innov Regul Sci. 2025;59(6):1336\u201355.","journal-title":"Ther Innov Regul Sci"},{"issue":"5","key":"1026_CR3","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1007\/s43441-025-00810-1","volume":"59","author":"G Santi Laurini","year":"2025","unstructured":"Santi Laurini G, Nikitina V, Broccoli M, Montanaro N, Motola D. Overview of orphan medicines in European union: an analysis of regulatory and technical-scientific aspects. Ther Innov Regul Sci. 2025;59(5):1087\u201397.","journal-title":"Ther Innov Regul Sci"},{"key":"1026_CR4","unstructured":"FDA. Rare Diseases at FDA. U.S. Food and Drug Administration. 2026"},{"issue":"11","key":"1026_CR5","first-page":"1097","volume":"23","author":"DA Hughes","year":"2005","unstructured":"Hughes DA, Tunnage B, Yeo ST. Drugs for exceptionally rare diseases: do they deserve special status? Pharmacoeconomics. 2005;23(11):1097\u2013112.","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"1026_CR6","doi-asserted-by":"publisher","first-page":"104698","DOI":"10.1016\/j.isci.2022.104698","volume":"25","author":"CIE Smith","year":"2022","unstructured":"Smith CIE, Bergman P, Hagey DW. Estimating the number of diseases \u2013 the concept of rare, ultra-rare, and hyper-rare. iScience. 2022;25(8):104698.","journal-title":"iScience"},{"issue":"7","key":"1026_CR7","doi-asserted-by":"publisher","first-page":"605","DOI":"10.7326\/0003-4819-125-7-199610010-00011","volume":"125","author":"TR Fleming","year":"1996","unstructured":"Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med. 1996;125(7):605\u201313.","journal-title":"Ann Intern Med"},{"key":"1026_CR8","unstructured":"FDA. Considerations for the use of the Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic Conditions with Known Biological Cause. US. Food and Drug Administration; Draft Guidance, 2026"},{"key":"1026_CR9","unstructured":"FDA BEST Resource. Biomarkers, EndpointS, and other Tools. FDA-NIH Biomarker Working Group; 2016 (updated 2021)"},{"key":"1026_CR10","doi-asserted-by":"crossref","unstructured":"Jeng LJB, et al. Surrogate Endpoints in Regulatory Decision-Making. Clin Pharmacol Ther. 2025","DOI":"10.1111\/cts.70445"},{"issue":"7","key":"1026_CR11","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1177\/09622802241259177","volume":"33","author":"F Stijven","year":"2024","unstructured":"Stijven F, Alonso A, Molenberghs G. Proportion of treatment effect explained: an overview of interpretations. Stat Methods Med Res. 2024;33(7):1278\u201396.","journal-title":"Stat Methods Med Res"},{"key":"1026_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.70317","author":"R Sharma","year":"2025","unstructured":"Sharma R, Gulati A, Chopra K. Accelerated approvals in oncology: trial design strategies and insights driving successful regulatory outcomes across three decades. Int J Cancer. 2025. https:\/\/doi.org\/10.1002\/ijc.70317.","journal-title":"Int J Cancer"},{"issue":"3","key":"1026_CR13","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1177\/17407745241309318","volume":"22","author":"K Hong","year":"2013","unstructured":"Hong K, Nugent B, Bandukwala A, et al. Pivotal trial characteristics and types of endpoints used to support Food and Drug Administration rare disease drug approvals between 2013 and 2022. Clin Trials. 2013;22(3):352\u201360.","journal-title":"Clin Trials"},{"key":"1026_CR14","doi-asserted-by":"crossref","unstructured":"Rossi A, et al. Biomarkers for gene therapy clinical trials of lysosomal storage diseases. Mol Ther. 2024","DOI":"10.1016\/j.ymthe.2024.06.003"},{"issue":"20","key":"1026_CR15","doi-asserted-by":"publisher","first-page":"10107","DOI":"10.3390\/ijms262010107","volume":"26","author":"AI Ayupova","year":"2025","unstructured":"Ayupova AI, et al. Surrogate biomarkers in gene therapy for orphan diseases. Int J Mol Sci. 2025;26(20):10107.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"1026_CR16","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.braindev.2023.07.005","volume":"45","author":"G Seo","year":"2023","unstructured":"Seo G, Kim S, Byun JC, Kwon S, Lee YJ. Evaluation of the neurofilament light chain as a biomarker in children with spinal muscular atrophy treated with nusinersen. Brain Dev. 2023;45(10):554\u201363.","journal-title":"Brain Dev"},{"issue":"10","key":"1026_CR17","doi-asserted-by":"publisher","first-page":"e16393","DOI":"10.1111\/ene.16393","volume":"31","author":"G Musso","year":"2024","unstructured":"Musso G, Bello L, Capece G, et al. Neurofilament light chain and profilin-1 dynamics in 30 spinal muscular atrophy type 3 patients treated with nusinersen. Eur J Neurol. 2024;31(10):e16393.","journal-title":"Eur J Neurol"},{"issue":"1","key":"1026_CR18","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3233\/JND-210735","volume":"9","author":"KA Rich","year":"2022","unstructured":"Rich KA, Fox A, Yalvac M, et al. Neurofilament levels in CSF and serum in an adult SMA cohort treated with Nusinersen. J Neuromuscul Dis. 2022;9(1):111\u20139.","journal-title":"J Neuromuscul Dis"},{"key":"1026_CR19","unstructured":"PMDA. Overview of Orphan Drug Designation. Pharmaceuticals and Medical Devices Agency, Japan. 2025"},{"issue":"1","key":"1026_CR20","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1186\/s12916-024-03800-6","volume":"22","author":"X Zhang","year":"2015","unstructured":"Zhang X, Peck CC, Wang Y, et al. Strength of clinical evidence supporting the United States Food and drug administration accelerated approvals from 2015 to 2022. BMC Med. 2015;22(1):587. https:\/\/doi.org\/10.1186\/s12916-024-03800-6.","journal-title":"BMC Med"},{"issue":"6","key":"1026_CR21","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1007\/s43441-025-00842-7","volume":"59","author":"T Yang","year":"2015","unstructured":"Yang T, Zhang H. Impact of China\u2019s drug review and approval system reform on pediatric drugs: an analysis based on registration data from 2015 to 2024. Ther Innov Regul Sci. 2015;59(6):1253\u201361.","journal-title":"Ther Innov Regul Sci"}],"container-title":["Therapeutic Innovation & Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-01026-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-026-01026-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-01026-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:02:14Z","timestamp":1793412134000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-026-01026-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1026"],"URL":"https:\/\/doi.org\/10.1007\/s43441-026-01026-7","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"value":"2168-4790","type":"print"},{"value":"2168-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"assertion":[{"value":"13 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}